Andrew Lipchik

Andrew Lipchik serves as Assistant Professor of Pharmaceutical Sciences at Wayne State University's College of Pharmacy. Holding a Ph.D. in Medicinal Chemistry and Molecular Pharmacology from Purdue University and postdoctoral training at Stanford University School of Medicine, his academic journey spans biochemistry, proteomics, and metabolic disease research.

• Stanford University School of Medicine: Postdoctoral Fellow, Department of Genetics (2014-2021)
• Purdue University: Ph.D. in Medicinal Chemistry and Molecular Pharmacology (2013)
• Xavier University: B.S. in Chemistry (2008)

Lipchik's research centers on immunometabolism, particularly the role of IgG antibodies in insulin resistance pathogenesis. His lab developed novel mitochondrial respiration assays correlating with clinical insulin sensitivity measurements (R² = 0.7), identifying IgG Fc glycosylation as a key mediator through FcRn interactions. Additional work characterizes B-cell repertoire plasticity in metabolic disease and develops kinase biosensors using terbium-sensitized luminescence. His publications span diabetes mechanisms, proteomics, and diagnostic biosensor development.

His recent publications reveal strong focus on immunometabolic interfaces, with recurring themes in antibody-mediated metabolic dysregulation, kinase signaling, and diagnostic biomarker development. Key trends include glycomics applications in metabolic disease and innovative biosensor technologies for kinase activity monitoring.

Scientific awards include:

• American Diabetes Association Pathway to Stop Diabetes Initiator Award (2018)
• Stanford US HUPO Career Development Award Nominee (2012)
• Alpha Sigma Nu National Honor Society (2008)

Lipchik co-founded KinaSense, LLC (2014-present) and secured significant funding including Stanford SPARK Translational Research Grant ($75,000) and NIH/NIDDK F32 Fellowship ($165,000). His teaching portfolio includes Pharmacotherapeutic Problem Solving, Pharmaceutical Sciences Colloquium, and research mentorship across multiple terms. Current laboratory work focuses on IgG-mediated insulin resistance mechanisms and therapeutic re-sensitization strategies using antibody-based interventions.